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1. Introduction 
The plant kingdom comprise a relatively small group within biodiversity, with about 
250,000 species, of which near 6%, has been studied for their biological activity, and 
only  about 15% has been studied in a phytochemical way. Arguably, the plant kingdom 
is the largest source of structural diversity in organic compounds, forming a reservoir of 
chemical structures which is not possible to find in another environment. In this sense, 
a large number of natural products isolated from plants (or their transformed products) 
are known, to have relevant biological activities showing an important applicative 
potential [1]. 
The quest for new chemical structures with antiproliferative properties, which can be 
used in the future as chemotherapeutic agents, is an active area of research stimulated 
by the discovery of new biological targets and the possibility of arising new drugs 
without undesirable side effects. In the past years, there has been an increasing 
interest in the development of new pharmaceuticals based on a nucleus present in 
natural products along with the increase of life-threatening diseases such as AIDS, 
cancer, hepatitis, etc. [2]. It is noteworthy that some semi synthetic compounds derived 
from a natural framework sometimes show higher bioactivity than the original natural 
product. Taking into account their broad range of biological activities, such as enzyme 
inducing, modulation of immune cell function, and cytotoxic against human tumor cell 
lines, [3-6] labdane diterpenes have attracted scientific interest. 
Analyzing the structure of molecules used in cancer therapy, most of them show 
nitrogenated functional groups in their framework like amide and carbamate moieties 
[7]. Recently, it has been reported a series of disubstituted 1,2,3-triazole exhibiting 
potent cytotoxicity in the nanomolar range and tubulin inhibitory activity in the low 
micromolar range [8]. This kind of compounds is considered an interesting unit in the 
design of anticancer drugs. Such heterocycle may act due to their dipolar character, 
rigidity, ability to form hydrogen bridge bonds or as simple connectors [9]. 
Synthetic organic chemists have gained great interest for 1,2,3-triazoles in the 
development of new biologically active molecules [10]. The triazole moiety does not 
occur in nature, but 1,2,3-triazole cores may form the basis of small-molecule 
pharmaceutical leads. Molecules containing this heterocyclic nucleus have being 
reported having anti-HIV, antimicrobial, anti-allergic, antifungal and antitumor activities 
[10].  
Grindelic acid (1) is a labdane-type diterpene that was reported as the main secondary 
metabolite from Grindelia chiloensis Cabr and G. pulchella Dunal var. pulchella 
(Asteraceae). This compound possesses a suitable C-14-side-chain for inserting 
functionalities carrying nitrogen and oxygen [11]. In a previous work, we have reported 
about the enhancement of the cytotoxicity of some sesquiterpenes and iridoids when 
their lipophilicity was increased by the introduction of alkyl and/or aryl-silyl 
functionalities on the natural framework [12]. 
In consideration of the above mentioned factors, herein we describe our findings aimed 
to the synthesis and cytotoxic evaluation of oxygenated and oxy-nitrogenated 
derivatives from grindelic acid (1). It should be emphasized that this diterpene can be 
isolated in significant quantities from the aforementioned natural sources. Furthermore, 
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these plants have a wide distribution in the Patagonian steppe zones of Argentina and 
Chile [13]. 
 
2. Result and Discussion  
2.1. Chemistry 
From Grindelia pulchella Dunal var. pulchella, we obtained the metabolites grindelic 
acid (1) and 1α-hydroxygrindelic acid (2), as reported earlier (Figure 1) [13]. 
Insert Figure 1 
 
In preliminary tests, compound 1 (main secondary metabolite) exhibited greater 
bioactivity than 2. Therefore, it was chosen as a starting material for the preparation of 
a series of thirty-six derivatives. Firstly, we prepared several oxygenated compounds 3-
10 taking advantage of the presence of the carboxylic acid group (Scheme 1). Methyl 
ester derivative 3 was obtained from 1 by direct esterification under standard 
conditions. Subsequent reduction of the ester group at the side chain, with LiAlH4 gave 
alcohol 4 in high yields. The oxidation of 4 under Parikh-Doering conditions and 
subsequent Wittig reaction using ethyl 2-(triphenylphosphoranylidene)-propanoate, led 
to the α,β-unsaturated ester 5 that after reduction with DIBAL-H afforded in good yields 
alcohol 6. Following the same sequence with ethyl(triphenyl-
phosphoranylidene)acetate, compounds 7 and 8, were obtained from 4. Epoxides 9 
and 10 were achieved by Katsuki-Sharpless asymmetric epoxidation of the allylic 
alcohol 8 using R,R-(+)-DET and S,S-(-)-DET, respectively. 
 
Insert Scheme 1 
Insert Legend Scheme 1 
 
Cycloaddition and multicomponent reactions are convergent procedures of high 
synthetic utility combining chemical and atomic efficiency. Within the first type, azide-
alkyne Huisgen cycloaddition is a powerful tool to prepare 1,2,3-triazoles in a 
straightforward manner [14]. Multicomponent Reactions (MCRs) are convergent 
reactions in which three or more starting materials react to form a product where, 
basically, all or most of the atoms contribute to the newly formed product. In MCRs a 
product is assembled according to a cascade of elementary chemical reactions. Thus, 
there is a network of reaction equilibrium which all finally flow into an irreversible step 
yielding the product. In this work, it was prepared a series of oxy-nitrogenated 
derivatives, compounds 11-22 by Ugi reaction, 27-32 and 37 by Huisgen 
cycloadditions, and 23-26 and 33-36 were prepared by classical chemistry. 
Noteworthy, in all proposals the natural product stereochemistry remained intact.  
Derivatives 11-22 were obtained by the Ugi reaction using 1 as carboxylic acid and 
acetone as a source of carbonyl group. Benzylamine (compounds 11-17), and aniline 
(compounds 18-22) were used as amines varying the corresponding isocyanides 
(Table 1). 
 
Insert Table 1 
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One of the most popular reactions within the click chemistry paradigm is the Cu(I)-
catalyzed 1,3-dipolar Huisgen cycloaddition of alkynes and azides. This reaction 
proceeds with great efficiency and selectivity in aqueous media and yields a triazole 
moiety [15]. Our first objective was to obtain azide 23 and alkyne 26, using as starting 
material alcohol 4 (see Scheme 2). 
Insert Scheme 2 
Insert Legend Scheme 2 
 
The coupling of azide 23 and various commercial alkynes, under Huisgen conditions, 
provided the 1,2,3-triazoles 27-28 in good yields. In a similar manner, the quasi 
symmetrical hybrid 29 was prepared from azide 23 and alkyne 26 (Table 2). 
 
Insert Table 2 
 
Using Huisgen conditions and adjusting 1 equivalent of the suitable di-alkyne per 2 
equivalents of the azide 23, the dimers 30-32 were achieved (see Table 3). Alkynes 
used for the preparations of compounds 30 and 31 are commercially available, and the 
alkyne used to arrive to compound 32 was synthesized according to the procedure 
described in the literature [16]. 
 
Insert Table 3 
 
The final set of derivatives was prepared with the aim to introduce the maximum of 
structural diversity at the final hybrid compounds. Thus, carbonylimidazole 33 was 
prepared by the reaction of alcohol 4 with carbonyldiimidazole (CDI) in CH2Cl2. 
Derivatives 34-35 were obtained from compound 33 by treatment with diverse amines. 
The use of ethylenediamine provided dimeric carbamate 36. Finally, Huisgen coupling 
of 35 with azide 23 yielded the hybrid triazol 37. 
Insert Scheme 3 
Insert Legend Scheme 3 
 
2.2. Antiproliferative activity  
The in vitro antiproliferative activity was evaluated using the National Cancer Institute 
(NCI) protocol after 48 h of drug exposure using the sulforhodamine B (SRB) assay. 
The results, expressed as GI50 values, are shown in Table 4. Derivatives 20-22, 31, 
and 36 were not evaluated due to their low solubility in DMSO under the testing 
conditions. 
From the growth inhibition results we can depict some preliminary structure-activity 
relationships. The group of oxygenated derivatives (3-10) is more active than the 
natural products (1-2) where they derive from, having GI50 values in all cell lines in the 
range 16-37 µM. In this series, compounds 5 and 7, both bearing an ethyl ester in the 
side chain, gave higher GI50 values (>30 µM) in the most resistant cell lines T-47D and 
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WiDr. When compared to the methyl ester analog 3, one could speculate with the 
bulkiness of the ester group on the side chain and its reverse effect on the activity. 
However, when the side chain was elongated through an Ugi reaction (compounds 11-
22) a clear enhancement in the antiproliferative activity was observed. In fact, 
compound 17 resulted the most active compound of the whole study with GI50 values in 
the range 0.95-1.9 µM. In this second group of compounds, a relationship between 
substituents and biological activity could not be established. When considering the 
derivatives of the Huisgen reaction 27-29, no improvement was observed in the activity 
when compared to the most active derivative 17. Finally, for the analogs bearing two 
grindelic scaffolds (29-32 and 36-37), the activity profile was variable. Thus, derivatives 
32 and 37 were inactive (GI50 >100 µM), whilst 30 and 34 showed GI50 values <10 µM 
against all cell lines tested. 
 
 
Insert Table 4 
 
 
3. Conclusion 
Given these results, the use of a natural product can be a viable strategy to prepare 
new active molecules. With adequate quantities of a natural product, and using 
accessible synthetic routes, it has been possible to obtain new structures exhibiting 
interesting bioactivities as antitumor agents. Grindelic acid (1) was the starting material 
for the transformation into several oxygenated, and oxy-nitrogenated moieties at the C-
14 side chain by means of diverse reactions. Our strategy allowed to reach thirty-five 
new compounds including functionalities such as epoxides, diamides, carbamates and 
1,2,3-triazoles, among others. A significant number of these synthetic derivatives 
showed higher activity than the natural product. It is noteworthy that the oxy-
nitrogenated and nitrogenated systems were more active than oxygenated ones, being 
the diamides the most active compounds. The N-benzyl-N-(1-(benzylamino)-2-methyl-
1-oxopropan-2-yl) amide of grindelic acid (17) proved to be the most active product in 
all cell lines tested. 
Finally, this work aims to demonstrate the possibility of achieving new antitumor 
leaders from molecular frameworks provided by nature, getting sometimes a dramatic 
enhance of the bioactivity through usual chemical transformations. 
 
4. Experimental 
4.1. Chemistry 
Unless stated otherwise, all solvents were purified by standard techniques. Reactions 
requiring anhydrous conditions were performed under argon. Anhydrous magnesium 
sulfate was used for drying solutions. Reactions were monitored by thin layer 
chromatography (TLC) on silica gel plates (60 F254), and were visualized by use of 
UV light, 2.5% phosphomolybdic acid in ethanol or vanillin with acetic and sulfuric 
acid in ethanol with heating [17]. Purification was performed by column 
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chromatography on silica gel (230-400 mesh) using n-hexane and ethyl acetate 
gradient as solvent. 1H NMR spectra were recorded on a Bruker 500 or 400 MHz, 13C 
NMR spectra were recorded at 100 MHz, and chemical shifts are reported relative to 
internal Me4Si (δ = 0). Melting points were determined by using an Electrothermal 
IA9000 melting point apparatus, are reported in degrees Celsius and are uncorrected. 
Optical rotations were recorded in a Perkin Elmer polarimeter 343. High resolution ESI 
mass spectra were obtained from a Fourier transform ion cyclotron resonance (FT-ICR) 
mass spectrometer, an RF-only hexapole ion guide, and an external electrospray ion 
source. HRMS spectra were obtained on a mass spectrometer Micromass AutoSpec. 
4.1.1. Preparation of grindelic acid methyl ester (3). 
Grindelic acid (1) (10 g, 31.2 mmol) was dissolved in 124 ml of dry Et2O (0,25 M) and 
was cooled at 0 ºC. A solution of CH2N2 in Et2O (1M) was added dropwise until the 
formation of N2 disappear. Reaction was checked by TLC. A few drops of acetic acid 
were added to quench the excess of diazomethane. Solvent was evaporated and the 
crude material was purified by silica gel chromatography to obtain 9.85 g, as yellow oil  
of 3, (29.46 mmol, 94% yield). [α]D20 = -117.2 (c 8.1, MeOH); IR νmax, cm-1 (KBr): 3030, 
2922, 1749 (C=O), 1672 (C=C), 991 (=C-H); 1H NMR (500MHz, CDCl3): δ 5.52 (s, 1H, 
H-7), 3.67 (s, 3H, OCH3), 2.75 (d, J =14, 1H, H-14 proR), 2.64 (d, J =14, 1H, H-14 
proS), 2.22 (m, 1H, H-12A), 2.07 (m, 2H, H-6A and H-11A), 1.87 (m, 3H, H-1 and H-
12B), 1.84 (m, 2H, H-6B and H-11B), 1.79 (s, 3H, H-17), 1.66 (m, 3H, H-3 and H-5), 
1.39 (m, 2H, H-2), 1.36 (s, 3H, H-16), 0.92 (s, 3H, H-19), 0.89 (s, 3H, H-18), 0.84 (s, 
3H, H-20); 13C NMR (100MHz, CDCl3): δ 171.9 (C-15), 134.9 (C-8), 126.5 (C-7), 90.6 
(C-9), 81.6 (C-13), 51.4 (OMe), 47.9 (C-14), 42.7 (C-5), 42.0 (C-3), 40.7 (C-10), 38.2 
(C-12), 33.2 (C-4), 32.9 (C-18), 32.8 (C-1), 28.5 (C-11), 27.3 (C-16), 24.2 (C-6), 22.4 
(C-19), 21.3 (C-17), 18.7 (C-2), 16.6 (C-20); HRMS-ES (m/z): calcd for C21H34O3 [M]+: 
334.2508, found 334.2560. All data are consistent with literature [13]. 
4.1.2. Preparation of grindelic alcohol (4). 
A solution of 5 gr of 3 (14.94 mmol) and 2.83 gr (74.74 mmol) of LiAlH4 in dry THF (150 
mL, 0.1 M) was refluxed during 2 h under Ar pressure. When reaction was completed 
the mixture was cooled and ethyl acetate was added until complete elimination of 
LiAlH4 residues. The crude was filtered and solids washed with 100 mL Et2O. Water 
(100 mL) was added and extracted with Et2O (3 x 50mL). Organic layers were dried 
with MgSO4 and resulting crude was purified by silica gel chromatography. 4.18 gr 
(13.64 mmol, 91% yield) of 4 was recovered as a white solid, mp 64-66 ºC. [α]D20 = -
131.7 (c 1.25, CHCl3); 1H NMR (400MHz, CDCl3): δ 5.51 (s, 1H), 3.97 (t, J = 11 Hz, 
1H), 3.69 (dd, J = 8.8 and 3 Hz, 1H), 2.10-1.95 (m, 4H), 1.91-1.72 (m, 3H), 1.82 (s, 
3H), 1.65-1.50 (m, 6H), 1.48-1.36 (m, 2H), 1.31 (s, 3H), 1.25 (m, 1H), 0.91 (s, 3H), 0.87 
(s, 3H), 0.82 (s, 3H); 13C NMR (100MHz, CDCl3): δ 134.5, 126.9, 91.1, 84.4, 60.0, 43.7, 
42.9, 41.9, 40.7, 40.5, 33.2, 32.9, 32.5, 27.5, 26.6, 24.1, 22.2, 21.1, 18.7, 16.6; HRMS-
ES (m/z): calcd for C20H34O2 [M]+: 306.2559, found 306.2548. All data are consistent 
with literature [13]. 
4.1.3. Preparation of (E)-ethyl 2-methyl-4-((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)but-2-enoate 
(5). 
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2.32 g of 4 (7.58 mmol), 6.31 ml of Et3N (4.6 g, 45.51 mmol) and 5.28 g of ethyl 2-
(triphenyl-phosphoranylidene)propanoate (15.17 mmol) were stirred with 30 ml of dry 
CH2Cl2 (0,25 M) and 6.1 ml of DMSO (0.8 ml/mmol of alcohol). When phosphorane 
was completely dissolved 3.62 g of SO3.Py complex (22.75 mmol) was added. 
Reaction was monitored by TLC. When reaction was completed, 20 ml of HCl (5%) 
was added. The layers were partitioned, and the aqueous phase was extracted with 
Et2O (3 x 20 ml). Organic layers were washed with water (3 x 20 ml) and aqueous NaCl 
saturated solution (1 x 20 ml), dried with MgSO4, filtered and concentrated. The crude 
was purified by silica gel column chromatography to give 5 (2.18 g, 5.6 mmol, 74% 
yield). [α]D20 = -36.1 (c 2.81, MeOH); 1H NMR (400MHz, CDCl3): δ 6.77 (t, J = 7 Hz, 
1H), 5.52 (s, 1H), 4.21 (q, J = 7 Hz, 2H), 2.61(dd, J = 14 and 8 Hz, 1H), 2.46 (dd, J = 
14 and 8 Hz, 1H), 2.15-1.95 (m 4H), 1.90-1.65 (m, 6H), 1.86 (s, 3H), 1.78 (s, 3H), 1.60-
1.35 (m, 4H), 1.31 (t, J = 7 Hz, 3H), 1.22 (s, 3H), 0.91 (s, 3H), 0.89 (s, 3H), 0.83 (s, 
3H); 13C NMR (100MHz, CDCl3): δ 168.2, 138.8, 135.0, 129.3, 126.5, 90.5, 83.4, 60.4, 
43.0, 42.6, 42.1, 40.7, 38.2, 33.2, 32.9, 32.8, 28.4, 27.5, 24.2, 22.4, 21.3, 18.8, 16.7, 
14.3, 12.6; HRMS-ES (m/z): calcd for C25H40O3 [M]+: 388.2977, found 388.2992.  
4.1.4. Preparation of (E)-2-methyl-4-((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)but-2-en-1-ol 
(6). 
896 mg of 5 (2.39 mmol) was dissolved in 24 ml of dry Et2O at 0 ºC. 5.26 ml of DIBAL-
H solution (0.1 M in cyclohexane, 5.26 mmol) was added dropwise. When reaction was 
completed 5 ml of water was added and reaction was stirred for 15 minutes at room 
temperature. Reaction mixture was dried with MgSO4, filtered through celite and 
purified by silica gel column chromatography to give 705 mg of 6 (2.12 mmol, 89% 
yield). [α]D20 = -28.2 (c 1.06, MeOH); 1H NMR (400MHz, CDCl3): δ 5.51 (s, 1H), 5.45 
(td, J = 7 and 2 Hz, 1H), 4.04 (s, 2H), 2.48 (dd, J = 14 and 8 Hz, 1H), 2.34 (dd, J = 14 
and 8 Hz, 1H), 2.13-1.92 (m, 4H), 1.88-1.80 (m, 2H), 1.79 (s, 3H), 1.71-1.68 (m, 2H), 
1.69 (s, 3H), 1.60-1.50 (m, 2H), 1.48-1.35 (m, 2H), 1.28-1.22 (m, 2H), 1.20 (s, 3H), 
0.92 (s, 3H), 0.89 (s, 3H), 0.83 (s, 3H); 13C NMR (100MHz, CDCl3): δ 136.4, 135.3, 
126.3, 122.9, 90.3, 83.9, 69.0, 42.6, 42.0, 41.9, 40.8, 38.0, 33.2, 32.9, 32.8, 28.4, 27.0, 
24.2, 22.3, 21.2, 18.8, 16.7, 14.0; HRMS-ES (m/z): calcd for C23H38O2 [M]+: 346.2872, 
found 346.2872.  
4.1.5. Preparation of (E)-ethyl 4-((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)but-2-enoate 
(7). 
995 mg of 4 (3.25 mmol), 2.72 ml of Et3N (1.97 g, 19.5 mmol) and 2.26 g of 
ethyl(triphenyl-phosphoranylidene)acetate (6.5 mmol) were stirred with 13 ml of dry 
CH2Cl2 (0,25 M) and 2.6 ml of DMSO (0.8 ml/mmol of alcohol). When phosphorane 
was completely dissolved, 1.55 g of SO3.Py complex (9.74 mmol) was added. Reaction 
was monitored by TLC. When reaction was completed, 20 ml of HCl (5%) was added. 
The layers were partitioned, and the aqueous phase was extracted with Et2O (3 x 20 
ml). Organic layers were washed with water (3 x 20 ml) and aqueous NaCl saturated 
solution (1 x 20 ml), dried with MgSO4, filtered and concentrated. Crude material was 
purified by silica gel column chromatography yielding 1.14 g of 7 (3.05 mmol, 94% 
yield). [α]D20 = -121.76 (c 1.71, MeOH); 1H NMR (500MHz, CDCl3): δ 6.95 (m, 1H), 5.87 
(d, J = 12 Hz, 1H), 5.52 (s, 1H), 4.21 (q, J = 7 Hz, 2H), 2.60 (m, 1H), 2.47 (m, 1H), 
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2.21-1.98 (m, 4H), 1.88-1.79 (m, 3H), 1.77 (s, 3H), 1.72-1.38 (m, 6H) 1.31 (t, J = 7 Hz, 
3H), 1.22 (s, 3H), 0.92 (s, 3H), 0.89 (s, 3H), 0.83 (s, 3H); 13C NMR (100MHz, CDCl3): δ 
166.6, 146.1, 134.9, 126.6, 123.6, 90.6, 82.6, 60.2, 46.8, 42.6, 42.0, 40.7, 38.2, 33.2, 
32.9, 32.8, 28.4, 27.5, 24.2, 22.4, 21.3, 18.8, 16.7, 14.3; HRMS-ES (m/z): calcd for 
C24H38O3 [M]+: 374.2821, found 374.2838.  
4.1.6. Preparation of (E)-2-methyl-4-((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)but-2-en-1-ol 
(8). 
426.2 mg of 7 (1.13 mmol) was dissolved in 12 ml of dry Et2O at 0 ºC. 2.5 ml of DIBAL-
H (0.1 M in cyclohexane, 2.5 mmol) was added dropwise. When reaction was 
completed 3 ml of water was added and reaction was stirred for 15 minutes at room 
temperature. Reaction mixture was dried with MgSO4, filtered through celite and 
purified by silica gel column chromatography to yield 8 (308.8 mg, 0.93 mmol, 82% 
yield). [α]D20 = -75.3 (c 6.22, MeOH); 1H NMR (500MHz, CDCl3): δ 5.66 (m, 2H), 5.49 
(bs, 1H), 4.09 (bs, 2H), 2.44 (m, 1H), 2.32 (m, 1H), 2.11-1.92 (m, 4H), 1.88-1.70 (m, 
2H), 1.76 (s, 3H), 1.70-1.60 (m, 4H), 1.58-1.45 (m, 2H), 1.44-1.20 (m, 2H), 1.18 (s, 3H), 
0.89 (s, 3H), 0.87 (s, 3H), 0.80 (s, 3H); 13C NMR (100MHz, CDCl3): δ 135.0, 131.6, 
129.4, 126.2, 90.3, 83.1, 62.4, 46.6, 42.5, 41.9, 40.6, 37.9, 33.1, 32.8, 32.7, 28.3, 27.0, 
24.1, 22.3, 21.2, 18.7, 16.6; HRMS-ES (m/z): calcd for C22H36O2 [M]+: 332.2715, found 
332.2718. 
4.1.7. Preparation of ((2S,3S)-3-(((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)methyl)oxiran-
2-yl)methanol (9). 
In a reaction flask containing powered activated 4 Å molecular sieves (30 mg), 130 mg 
of 8 (0.39 mmol) was dissolved in 4 ml of dry CH2Cl2 (0.1 M) and cooled at -20 ºC 
under argon atmosphere. 138.5 µl of Ti(OPr-i)4 (133.46 mg, 0.47 mmol) and 93.8 µl of 
(R,R)-(+)-DET (112.98 mg, 0.55 mmol) were added sequentially. The mixture was 
stirred at the same temperature for 20 min, and TBHP (0.14 ml, 5.5 M in isooctane, 
0.78 mmol) was added slowly. After the addition, the reaction was maintained with 
stirring for 12 h at low temperature. Tartaric acid aqueous solution (15%w/v) was 
added and the stirring was continued at room temperature for 1 h. The phases were 
separated and the aqueous phase was extracted with CH2Cl2 (3 x 3 ml). The combined 
organic phase were washed with brine, concentrated, diluted with Et2O, and treated 
with precooled, at 0 ºC, 15%(w/v) NaOH aqueous solution. The two-phase mixture was 
stirred vigorously for 15 minutes at 0 ºC. The organic phase was separated, and the 
aqueous phase was extracted with CH2Cl2 (3 x 3 ml). The combined organic phase 
were washed with brine, dried, filtered, concentrated, and purified by silica gel column 
chromatography to yield 9 (96.8 mg, 0.28 mmol, 71% yield). [α]D20 = -97.3 (c 1.1, 
MeOH); 1H NMR (500MHz, CDCl3): δ 5.51 (s, 1H), 3.92 (dd, J = 12 and 2 Hz, 1H), 3.66 
(dd, J = 12 and 4 Hz, 1H), 3.06 (m, 1H), 2.92 (m, 1H), 2.15-2.00 (m, 3H), 1.98-1.80 (m, 
2H), 1.88-1.77 (m, 2H) 1.78 (s, 3H), 1.71-1.65 (m, 2H), 1.62-1.51 (m, 4H), 1.48-1.35 
(m, 1H), 1.30 (s, 3H), 1.28-1.18 (m, 1H) 0.90 (s, 3H), 0.89 (s, 3H), 0.83 (s, 3H); 13C 
NMR (100MHz, CDCl3): δ 135.0, 126.5, 90.6, 82.3, 61.7, 58.4, 53.4, 45.4, 42.6, 42.0, 
40.7, 38.5, 33.2, 32.9, 32.8, 28.3, 28.0, 24.2, 22.4, 21.2, 18.8, 16.7; HRMS-ES (m/z): 
calcd for C22H36O3 [M]+: 348.2664, found 348.2672. 
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4.1.8. Preparation of ((2R,3R)-3-(((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)methyl)oxiran-
2-yl)methanol (10). 
The procedure used above to obtain 9 was applied again to 8 (64 mg, 0.19 mmol), 
using the (S,S)-(-)-DET instead of (R,R)-(+)-DET, to yield 10 (57.0 mg, 0.16 mmol, 
85%.yield). [α]D20 = -137.6 (c 2.82, MeOH); 1H NMR (500MHz, CDCl3): δ 5.49 (s, 1H), 
3.89 (dd, J = 12 and 2 Hz, 1H), 3.63 (dd, J = 12 and 4 Hz, 1H), 3.10 (m, 1H), 2.90 (m, 
1H), 2.19-1.95 (m, 5H), 1.86-1.73 (m, 2H), 1.74 (s, 3H), 1.72-1.60 (m, 2H), 1.58-1.49 
(m, 2H), 1.48-1.35 (m, 2H), 1.32 (s, 3H), 1.28-1.17 (m, 2H) 0.91 (s, 3H), 0.88 (s, 3H), 
0.82 (s, 3H); 13C NMR (100MHz, CDCl3): δ 135.1, 126.3, 90.4, 82.2, 61.8, 58.1, 53.8, 
45.8, 42.8, 42.0, 40.7, 39.2, 33.2, 33.0, 32.7, 28.4, 27.4, 24.2, 22.4, 21.3, 18.8, 16.7; 
HRMS-ES (m/z): calcd for C22H36O3 [M]+: 348.2664, found 348.2672. 
4.1.9. General procedure for Ugi reaction. Preparation of 2-(N-benzyl-2-
((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-
spiro[furan-2,1'-naphthalene]-5-yl)acetamido)-N-tert-butyl-2-methylpropanamide (11). 
A solution of acetone (0.030 mL, 0.41 mmol), and benzylamine (0.038 mL, 0.35 mmol) 
in methanol (0.7 mL, 0.5 M) were stirred for 3 hours. After that, grindelic acid (107.1 
mg, 0.35 mmol) and tert-butyl-isocyanide (0.044 mL, 0.38 mmol) were added. Reaction 
mixture was stirred for 24 h. The solvent was removed under reduced pressure and the 
crude reaction mixture was purified by flash chromatography on silica gel to afford the 
desired product 11 (111 mg, 59% yield) as a white solid: mp 72-74 ºC. [α]D20 = -137.6 
(c 2.82, MeOH); 1H NMR (500MHz, CDCl3): δ 7.37 (m, 2H, H-3’ and H-5’), 7.29 (m, 3H, 
H-2’, H-4’ and H-6’), 5.59 (s, 1H, N-H), 5.46 (s, 1H, H-7), 5.07 (d, J = 14.4 Hz, 1H, H-
7’A), 4.45 (d, J = 14.4 Hz, 1H, H-7’B), 2.89 (d, J = 11.6 Hz, 1H, H-14A), 2.56 (d, J = 
11.6 Hz, 1H, H-14B), 2.07 (m, 1H, H-11A), 2.04 (m, 3H, H-6A and H-12), 1.86 (m, 1H, 
H-6B), 1.73 (m, 1H, H-11B), 1.62 (m, 1H, H-5), 1.56 (s, 3H, H-17), 1.55 (m, 2H, H-1), 
1.52 (m, 2H, H-2), 1.40 (s, 3H, H-16), 1.38 (s, 6H, H-3’’ and H-4’’), 1.36 (s, 9H, H-2’’’, 
H-3’’’ and H-4’’’), 1.18 (m, 1H, H-3A), 1.13 (m, 1H, H-3B), 0.92 (s, 3H, H-19), 0.88 (s, 
3H, H-18), 0.81 (s, 3H, H-20); 13C NMR (100MHz, CDCl3): δ 174.0 (C-1’’), 171.9 (C-
15), 139.0 (C-1’), 135.0 (C-8), 128.8 (2C, C-3 and C-5’), 127.1 (C-7), 126.4 (C-4’), 
125.7 (2C, C-2 and C-6’), 90.4 (C-9), 83.1 (C-13), 63.1 (C-2’’), 50.7 (C-1’’’), 48.0 (C-
14), 47.6 (C-7’), 43.0 (C-5), 42.0 (C-3), 40.6 (C-10), 39.7 (C-12), 33.2 (C-4), 33.1 (C-
18), 32.6 (C-1), 28.6 (3C, C-2’’’, C-3’’’ and C-4’’’), 28.3 (C-11),  27.7 (C-16), 24.4 (C-6), 
24.3 (2C, C-3’’ and C-4’’), 22.3 (C-19), 21.2 (C-17), 18.7 (C-2), 16.6 (C-20); HRMS-ES 
(m/z): calcd for C35H54N2O3 [M]+: 550.3734, found 550.3722. 
4.1.10. Preparation of 2-(N-benzyl-2-((1'R,5S,8α'S)-2',5,5',5',8α'-pentamethyl-
4,4α',5,5',6',7',8',8α-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)acetamido)-2-
methyl-N-(2,3,3-trimethylbutan-2-yl)propanamide (12). 
This compound was prepared by General procedure for Ugi reaction using 
benzylamine and 1,1,3,3-tetramethylbutylisocyanide to obtain 444 mg of 12 (75% yield) 
as a clear oil color less oil. [α]D20 = -66.73 (c 1.2, CHCl3); 1H NMR (500MHz, CDCl3): δ 
7.38 (m, 2H), 7.30 (m, 3H), 5.63 (s, 1H), 5.45 (s, 1H), 5.00 (d, J = 18 Hz, 1H), 4.48 (d, J 
= 18 Hz, 1H), 2.89 (d, J = 15 Hz, 1H), 2.57 (d, J = 15 Hz, 1H), 2.15-2.00 (m, 5H), 1.91-
1.82 (m, 1H), 1.77-1.65, (m, 2H), 1.61 (s, 3H), 1.57 (m, 1H), 1.54-1.49 (m, 2H), 1.45 (s, 
6H), 1.40 (s, 3H), 1.38 (s, 3H), 1.37(s, 3H), 1.30-1.25 (m, 1H), 1.22-1.14 (m, 1H) 1.01 
(s, 9H), 0.91 (s, 3H), 0.88 (s, 3H), 0.81 (s, 3H); 13C NMR (100MHz, CDCl3): δ 173.4, 
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171.9, 138.9, 135.1, 128.8 (2C), 127.1, 126.4, 125.8 (2C), 90.3, 83.2, 63.1, 54.9, 53.0, 
48.0, 47.6, 43.0, 42.0, 40.6, 39.5, 33.2, 33.1, 32.6, 31.6 (3C), 31.5, 28.5, 28.4 (2C), 
27.7, 24.4, 24.2, 22.3, 21.2, 18.7, 16.6; HRMS-ES (m/z): calcd for C38H60N2O3 [M]+: 
606.4760, found 606.4756. 
4.1.11. Preparation of 2-(N-benzyl-2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)acetamido)-N-
cyclohexyl-2-methylpropanamide (13). 
This compound was prepared by General procedure for Ugi reaction using 
benzylamine and cyclohexyl isocyanide to obtain 378 mg of 13 (71% yield) as a white 
solid: mp 81-83 ºC. [α]D20 = -91.08 (c 1.0, CHCl3); 1H NMR (500MHz, CDCl3): δ  7.36 
(m, 4H), 7.26 (m, 1H), 5.55 (d, J = 8 Hz,, 1H), 5.48 (s, 1H), 5.10 (d, J = 18 Hz, 1H), 
4.43 (d, J = 18 Hz, 1H), 3.76 (m, 1H), 2.84 (d, J = 14 Hz, 1H), 2.51 (d, J = 14 Hz, 1H), 
2.09-1.81 (m, 7H), 1.75-1.60 (m, 10H) 1.54 (bs, 3H), 1.45-1.30 (m, 3H), 1.40 (s, 6H), 
1.37 (s, 3H), 1.28-1.05 (m, 5H) 0.91 (s, 3H), 0.88 (s, 3H), 0.80 (s, 3H); 13C NMR 
(100MHz, CDCl3): δ 174.0, 172.0, 139.1, 135.0, 128.7 (2C), 127.0, 126.4, 125.7 (2C), 
90.4, 83.0, 62.5, 48.2, 47.8, 47.4, 43.1, 42.1, 40.6, 39.7, 33.2 (2C), 33.0, 32.6, 28.2, 
27.8, 25.7, 24.9 (2C), 24.5 (2C), 24.3, 24.2, 22.3, 21.2, 18.7, 16.6; HRMS-ES (m/z): 
calcd for C37H56N2O3 [M]+: 576.4291, found 576.4288. 
4.1.12. Preparation of 2-(N-benzyl-2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)acetamido)-N-
(2,6-dimethylphenyl)-2-methylpropanamide (14). 
This compound was prepared by General procedure for Ugi reaction using 
benzylamine and 2,6-dimethylphenyl isocyanide to obtain 350 mg of 14 (63% yield) as 
a white solid: mp 181-183 ºC. [α]D20 = -74.63 (c 1.023, CHCl3); 1H NMR (500MHz, 
CDCl3): δ  7.29 (m, 5H), 7.00 (m, 3H), 5.41 (bs, 1H), 5.37 (s, 1H), 5.07 (d, J = 19 Hz, 
1H), 4.54 (d, J = 19 Hz, 1H), 2.89 (d, J = 15 Hz, 1H), 2.78 (d, J = 15 Hz, 1H ), 2.56 (d, J 
= 15 Hz, 1H), 2.45 (d, J = 15 Hz, 1H), 2.28 (bs, 6H), 2.15-1.90 (m, 4H), 1.59 (s, 3H), 
1.54 (s, 3H), 1.49-1.18 (10H), 1.37 (s, 3H), 0.82 (s, 3H), 0.81 (s, 3H), 0.78 (s, 3H); 13C 
NMR (100MHz, CDCl3): δ 175.1, 172.1, 138.8, 134.9, 128.7 (2C), 128.5 (2C), 127.8 
(2C), 127.2, 127.0, 126.6, 125.7 (2C), 82.9, 62.5, 47.6, 47.5, 43.8, 43.2, 42.1, 40.5, 
39.7, 39.6, 33.2 (2C), 32.6, 28.2, 28.1, 27.7, 24.5, 24.3 (2C), 22.2, 21.3, 19.5, 18.7, 
16.6; HRMS-ES (m/z): calcd for C39H54N2O3 [M]+: 598.4134, found 598.4149. 
4.1.13. Preparation of 2-(N-benzyl-2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)acetamido)-N-
butyl-2-methylpropanamide (15). 
This compound was prepared by General procedure for Ugi reaction using 
benzylamine and butyl isocyanide to obtain 438 mg of 15 (79% yield) as a white solid: 
mp 70-72 ºC. [α]D20 = -78.53 (c 1.34, CHCl3); 1H NMR (500MHz, CDCl3): δ 7.35 (m, 
5H), 5.77 (bs, 1H), 5.51 (s, 1H), 5.16 (d, J = 19 Hz, 1H), 4.41 (d, J = 19 Hz, 1H), 3.32 
(m, 1H), 3.23 (m, 1H), 2.83 (d, J = 14 Hz, 1H), 2.49 (d, J = 14 Hz, 1H), 2.23-2.00 (m, 
5H), 2.00-1.97 (m, 2H), 1.92-1.80 (m, 4H), 1.80-1.60 (m, 2H), 1.60-1.30 (m 4H), 1.56 
(bs, 3H), 1.42 (bs, 3H), 1.41 (bs, 3H), 1.36 (s, 3H), 0.93 (t, J = 6 Hz 3H), 0.92 (s, 3H), 
0.89 (s, 3H), 0.81 (s, 3H); 13C NMR (100MHz, CDCl3): δ 175.1, 172.1, 138.9, 134.9, 
128.7 (2C), 127.0, 126.6, 125.7 (2C), 90.5, 82.9, 62.4, 47.7, 47.6, 43.3, 42.1, 40.6, 
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39.8, 39.7, 33.2 (2C), 32.5, 31.8, 28.1, 27.7, 24.5, 24.4, 24.3, 22.2, 21.3, 20.2, 18.7, 
16.6, 13.8; HRMS-ES (m/z): calcd for C35H54N2O3 [M]+: 550.4134, found 550.4132. 
4.1.14. Preparation of 2-(N-benzyl-2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)acetamido)-2-
methyl-N-(2-morpholinoethyl)propanamide (16). 
This compound was prepared by General procedure for Ugi reaction using 
benzylamine and 2-morpholinoethyl isocyanide to obtain 106.8 mg of 16 (79% yield) as 
a white solid: mp 164-166 ºC. [α]D20 = -87.98 (c 1.32, CHCl3); 1H NMR (500MHz, 
CDCl3): δ  7.27 (m, 4H), 7.18 (m, 1H), 6.20 (bs, 1H), 5.41 (s, 1H), 5.04 (d, J = 19 Hz, 
1H), 4.29 (d, J = 19 Hz, 1H), 3.65 (m, 4H), 3.30 (m, 2H), 2.73 (d, J = 14 Hz, 1H), 2.50-
2.41 (m, 6H), 2.38 (d, J = 14 Hz, 1H), 2.10-1.90 (m, 4H), 1.85-1.50 (m, 4H), 1.47 (bs, 
3H), 1.45-1.09 (m, 4H), 1.35 (bs, 3H), 1.28 (bs, 3H), 1.25 (s, 3H), 1.22-1.03 (m, 2H) 
0.83 (s, 3H), 0.80 (s, 3H), 0.73 (s, 3H); 13C NMR (100MHz, CDCl3): δ 175.4, 172.1. 
139.1, 134.9, 128.7 (2C), 126.9, 126.6, 125.7 (2C), 90.4, 82.9, 67.1, 62.3, 56.9, 53.3 
(3C), 47.5, 47.2, 43.1, 42.2, 41.9, 40.5, 39.7, 36.1, 33.2 (2C), 28.1, 27.8, 24.8, 24.3, 
23.4, 22.2, 21.3, 18.7, 16.6; HRMS-ES (m/z): calcd for C37H58N3O4 [M+H]+: 608.4427, 
found 608.4443. 
4.1.15. Preparation of N-benzyl-2-methyl-2-(2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)-N-
phenylacetamido)propanamide (17). 
This compound was prepared by General procedure for Ugi reaction using 
benzylamine and benzylisocyanide to obtain 528 mg of 17 (97% yield) as a white solid: 
mp 76-78 ºC. [α]D20 = -72.91 (c 1.18, CHCl3); 1H NMR (500MHz, CDCl3): δ  7.25 (m, 
10H), 6.94 (m, 1H), 5.41 (s, 1H), 5.04 (d, J = 19 Hz, 1H), 4.50 (dd, J = 19 and 6 Hz, 
1H), 4.34 (m, 2H), 2.76 (d, J = 14 Hz, 1H), 2.41 (d, J = 19 Hz, 1H), 2.15-1.59 (m, 6H), 
1.58-1.10 (m, 6H), 1.47 (bs, 3H), 1.37 (bs, 3H), 1.36 (bs, 3H), 1.22 (s, 3H), 1.00 (m, 
1H), 0.81 (s, 3H), 0.75 (s, 3H), 0.73 (s, 3H); 13C NMR (100MHz, CDCl3): δ 175.1, 
172.1, 138.8 (2C), 134.9, 128.7 (2C), 128.5 (2C), 127.8 (2C), 127.2, 127.0, 126.6, 
125.7 (2C), 90.4, 82.9, 62.5, 47.6, 47.5, 43.8, 43.2, 42.1, 40.5, 39.7, 33.2 (2C), 32.6, 
28.2, 27.7, 24.5, 24.3 (2C), 22.2, 21.3, 18.7, 16.6; HRMS-ES (m/z): calcd for 
C38H52N2O3 [M]+: 584.3978, found 584.3956. 
4.1.16. Preparation of N-tert-butyl-2-methyl-2-(2-((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-
pentamethyl-4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)-
N-phenylacetamido)propanamide (18). 
This compound was prepared by General procedure for Ugi reaction using aniline and 
tert-butyl-isocyanide to obtain 389.4 mg of 18 (78% yield) as a white solid: mp 74-76 
ºC. [α]D20 = -65.36 (c 11.37, CHCl3); 1H NMR (500MHz, CDCl3): δ 7.36 (m, 3H), 7.21 
(m, 2H), 5.69 (s, 1H), 5.38 (s, 1H), 2.45 (d, J = 15 Hz, 1H), 2.24 (d, J = 15 Hz, 1H), 
2.15 (m, 1H), 1.99 (m, 3H), 1.82-1.54 (m, 4H), 1.53 (bs, 3H), 1.51-1.42 (m, 3H), 1.38 
(s, 9H), 1.33 (s, 3H), 1.32 (s, 3H), 1.22 (s, 3H), 1.20-1.08 (m, 2H), 0.87 (s, 3H), 0.81 (s, 
3H), 0.77 (s, 3H); 13C NMR (100MHz, CDCl3): δ 174.0, 170.8, 139.9, 135.2, 130.6, 
130.2, 129.4 (2C), 128.4, 126.0, 123.9, 90.0, 83.5, 63.0, 50.8, 48.1, 42.8, 42.0, 40.7, 
38.8, 33.0, 32.9, 28.7, 28.6 (3C), 27.6, 25.9, 24.8, 24.1, 22.4, 21.2, 18.7, 16.7; HRMS-
ES (m/z): calcd for C34H52N2O3 [M]+: 536.3978, found 536.3961. 
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4.1.17. Preparation of N-(2,6-dimethylphenyl)-2-methyl-2-(2-((1'R,5S,8a'S)-
2',5,5',5',8a'-pentamethyl-4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-
naphthalene]-5-yl)-N-phenylacetamido)propanamide (19). 
This compound was prepared by General procedure for Ugi reaction using aniline and 
2,6-dimethylphenyl isocyanide to obtain 140 mg of 19 (26% yield) as a white solid: mp 
90-92 ºC. [α]D20 = -62.58 (c 10.47, CHCl3); 1H NMR (500MHz, CDCl3): δ 7.41 (m, 3H), 
7.30 (m, 3H), 7.20 (s, 1H), 7.10 (m, 2H), 5.40 (s, 1H), 2.49 (d, J = 18 Hz, 1H), 2.32 (bs, 
6H), 2.30-2.15 (m, 4H), 2.12-1.89 (m, 4H), 1.80-1.58 (m, 6H) 1.53 (bs, 6H), 1.48 (bs, 
3H), 1.32 (s, 3H), 0.86 (s, 3H), 0.79 (s, 3H), 0.76 (s, 3H); 13C NMR (100MHz, CDCl3): δ 
172.9, 171.0, 139.9, 139.7, 135.3, 130.7, 130.4, 129.5 (2C), 128.6, 128.1 (2C), 126.9, 
126.0, 124.3, 118.0, 90.0, 83.5, 63.0, 47.9, 42.8, 41.9, 40.7, 38.7, 33.2, 33.0, 32.9, 
28.7, 27.6, 26.1, 25.5, 24.1, 22.4, 21.3, 18.7, 18.5 (2C), 16.7; HRMS-ES (m/z): calcd 
for C38H52N2O3 [M]+: 584.3978, found 584.3971. 
4.1.18 Preparation of N-butyl-2-methyl-2-(2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)-N-
phenylacetamido)propanamide (20). 
This compound was prepared by General procedure for Ugi reaction using aniline and 
butyl isocyanide to obtain 115 mg of 20 (23% yield) as a white solid: mp 187-189 ºC. 
[α]D20 = -52.86 (c 1.17, CHCl3); 1H NMR (500MHz, CDCl3): δ 7.38 (m, 3H), 7.27 (m, 
2H), 5.87 (t, J = 6 Hz, 1H), 5.41 (s, 1H), 3.32 (m, 2H), 2.47 (d, J = 15 Hz, 1H), 2.26 (d, 
J = 15 Hz, 1H), 2.15 (m, 1H), 2.05-1.90 (m, 3H), 1.85-1.72 (m, 1H), 1.70-1.60 (m, 4H) 
1.60-1.45 (m, 4H), 1.52 (bs, 3H), 1.45-1.25 (m, 3H), 1.35 (s, 3H), 1.32 (s, 3H), 1.31 (s, 
3H), 1.15 (m, 1H) 0.95 (t, J = 7 Hz, 3H), 0.89 (s, 3H), 0.84 (s, 3H), 0.79 (s, 3H); 13C 
NMR (100MHz, CDCl3): δ 174.9, 171.0, 140.0, 135.2, 130.7, 130.3, 129.4 (2C), 128.4, 
126.0, 90.1, 83.5, 62.5, 47.9, 42.9, 42.0, 40.7, 39.7, 38.9, 33.1, 33.0, 32.9, 31.7, 28.6, 
27.6, 25.9, 25.1, 24.1, 22.4, 21.3, 20.2, 18.7, 16.7, 13.8; HRMS-ES (m/z): calcd for 
C34H52N2O3 [M]+: 536.3978, found 536.3962. 
4.1.19. Preparation of N-benzyl-2-methyl-2-(2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)-N-
phenylacetamido)propanamide (21). 
This compound was prepared by General procedure for Ugi reaction using aniline and 
benzylisocyanide to obtain 229 mg of 21 (43% yield) as a white solid: mp 194-196 ºC. 
[α]D20 = -57.56 (c 1.16, CHCl3); 1H NMR (500MHz, CDCl3): δ 7.37 (m, 7H), 7.27 (m, 
3H), 6.14 (t, J = 6 Hz, 1H), 5.41 (s, 1H), 4.60 (dd, J = 15 and 6 Hz, 1H), 4.49 (dd, J = 
15 and 6 Hz, 1H), 2.47 (d, J = 15 Hz, 1H), 2.26 (d, J = 15 Hz, 1H), 2.20-2.08 (m, 1H), 
2.07-1.81 (m, 3H), 1.75-1.55 (m, 5H) 1.53 (bs, 3H), 1.51-1.42 (m, 4H) 1.37 (s, 6H), 
1.30 (s, 3H), 1.15 (m, 1H), 0.89 (s, 3H), 0.82 (s, 3H), 0.79 (s, 3H); 13C NMR (100MHz, 
CDCl3): δ 174.9, 171.1, 139.8, 138.7, 135.2, 130.7, 130.4, 129.5 (2C), 128.6 (2C), 
128.5, 127.8 (2C), 127.3, 126.0, 90.1, 83.5, 62.6, 47.9, 43.9, 42.9, 42.0, 40.6, 38.8, 
33.2, 33.0, 32.9, 28.7, 27.6, 25.7, 25.2, 24.1, 22.5, 21.3, 18.7, 16.7; HRMS-ES (m/z): 
calcd for C37H51N2O3 [M+H]+: 571.3900, found 571.3872. 
4.1.20. Preparation of N-cyclohexyl-2-methyl-2-(2-((1'R,5S,8a'S)-2',5,5',5',8a'-
pentamethyl-4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)-
N-phenylacetamido)propanamide (22). 
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This compound was prepared by General procedure for Ugi reaction using aniline and 
cyclohexyl isocyanide to obtain 481 mg of 22 (92% yield) as a white solid: mp 222-224 
ºC. [α]D20 = -60.91 (c 1.33, CHCl3); 1H NMR (500MHz, CDCl3): δ 7.38 (m, 3H), 7.23 (m, 
2H), 5.68 (d, J = 8 Hz, 1H), 5.40 (s, 1H), 3.79 (m, 1H), 2.45 (d, J = 15 Hz, 1H), 2.25 (d, 
J = 15 Hz, 1H), 2.12-1.98 (m, 1H), 1.95-1.78 (m, 5H), 1.75-1.50 (m, 9H), 1.53 (bs, 3H), 
1.42-1.30 (m, 3H), 1.33 (s, 3H), 1.31 (s, 3H), 1.28 (s, 3H), 1.27-1.02 (m, 5H), 0.87 (s, 
3H), 0.82 (s, 3H), 0.77 (s, 3H); 13C NMR (100MHz, CDCl3): δ 173.9, 170.9, 140.0, 
135.2, 130.6, 130.3, 129.4 (2C), 128.4, 125.9, 90.0, 83.5, 62.6, 48.4, 48.0, 42.8, 42.0, 
40.6, 38.7, 33.2, 33.0 (2C), 32.9, 29.7, 28.7, 27.6, 25.8, 25.7, 25.1, 24.9 (2C), 24.1, 
22.47, 21.2, 18.7, 16.7; HRMS-ES (m/z): calcd for C36H54N2O3 [M]+: 562.4134; found 
562.4127. 
4.1.21. Preparation of (1'R,4a'S,5S,8a'S)-5-(2-azidoethyl)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene] (23). 
Alcohol 4 (2 g, 6.53 mmol) was dissolved in dry CH2Cl2 (65 mL) and the solution was 
cooled to 0 ºC. Triethylamine (1.8 mL, 13.06 mmol) was added via syringe followed by 
methanesulfonyl chloride (758 µL, 9.78 mmol) in one portion. After 4.5 h, the reaction 
mixture was diluted with CH2Cl2 (20 mL), washed with H2O (30 mL) and brine (30 mL), 
dried with MgSO4, filtered, and evaporated under reduced pressure to leave a yellow 
residue. The crude residue was purified by flash-chromatography column on silica gel, 
using n-hexane/ethyl acetate as the eluent. The mesylate obtained (2.26 g, 5.8 mmol, 
90% yield) was dissolved in dry DMF (37 mL, 0.16 M). Sodium azide (764 mg, 11.7 
mmol) was added and the mixture was stirred at 40 ºC. After 24 h, the reaction mixture 
was diluted with Et2O (40 mL), washed with H2O (3 x 20 mL) and brine (30 mL), dried 
with MgSO4, filtered, and concentrated under reduced pressure. The crude oil was 
purified by column chromatography on silica gel, using n-hexane/ethyl acetate as the 
eluent, to afford 23 as an oil (1.55 g, 80% yield). [α]D20 = -140.8 (c 1.15, CHCl3); IR νmax, 
cm-1 (KBr): 2968, 2924, 2870, 2098 (azide), 1460, 1377, 1315, 1267, 1003, 874, 677.; 
1H NMR (500MHz, CDCl3): δ 5.50 (s, 1H, H-7), 3.42 (m, 1H, H-15A), 3.32 (m, 1H, H-
15B), 2.07 (m. 1H, H-11A), 2.05 (m, 1H, H-6A), 1.98 (m, 1H, H-12A), 1.97 (m, 1H, H-
14A), 1.86 (m, 1H, H-14B), 1.83 (m, 1H, H-6B), 1.81 (m, 1H, H-11B), 1.77 (m, 1H, H-
12B), 1.76 (s, 3H, H-17), 1.69 (m, 1H, H-5), 1.65 (m, 1H, H-1A), 1.57 (m, 2H, H-2), 1.41 
(m, 1H, H-1B), 1.39 (m, 1H, H-3A), 1.23 (s, 3H, H-16), 1.22 (m, 1H, H-3B), 0.91 (s, 3H, 
H-19), 0.89 (s, 3H, H-18), 0.82 (s, 3H, H-20); 13C NMR (100MHz, CDCl3): δ 135.0 (C-
8), 126.4 (C-7), 90.4 (C-9), 81.5 (C-13), 48.2 (C-15), 42.6 (C-5), 42.1 (C-14), 42.0 (C-
3), 40.7 (C-10), 39.5 (C-12), 33.2 (C-4), 33.0 (C-18), 32.8 (C-1), 28.2 (C-11), 26.9 (C-
16), 24.2 (C-6), 22.3 (C-19), 21.2 (C-17), 18.8 (C-2), 16.8 (C-20); HRMS-ES (m/z): 
calcd for C20H34N3O [M+H]+: 332.2702, found 332.2709. 
4.1.22. Preparation of 3-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-4,4a',5,5',6',7',8',8a'-
octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)propanal (24). 
To an oxalyl chloride solution (60 µL, 0.622 mmol) in CH2Cl2 (8 mL) at -78 ºC was 
added dropwise DMSO (90 µL, 1.24 mmol), and the resulting mixture was stirred for 15 
min. A solution of 4 (150.5 mg, 0.49 mmol) in CH2Cl2 (2 mL) was added dropwise at -
78 ºC. The mixture was stirred for 30 min. Triethylamine (0.7 ml, 4.9 mmol) was added 
dropwise and the resultant mixture was gradually warmed to room temperature and 
stirred for 7h. The mixture was quenched with water (10 mL) and CH2Cl2 (10 mL). The 
organic layer was washed with brine, dried over MgSO4, filtered and concentrated in 
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vacuum. Purification of the residue by silica gel column chromatography (n-
hexane/ethyl acetate, 85:15) gave the aldehyde 24 (148 mg, 99%). [α]D25 = -72.14 (c 
0.14, CHCl3); 1H NMR (500MHz, CDCl3): δ 9.82 (s, 1H), 5.52 (s, 1H), 2.80 (dd, J = 13 
and 2 Hz, 1H), 2.60 (dd, J = 13 and 2 Hz, 1H), 2.08 (m, 4H), 1.87 (m, 3H), 1.76 (bs, 
3H), 1.57 (m, 5H), 1.33 (s, 3H), 1.22 (m,1H), 0.91 (s, 3H), 0.88 (s, 3H), 0.83 (s, 3H); 
13C NMR (100MHz, CDCl3): δ 202.8, 134.6, 126.8, 80.9, 57.1, 42.7, 42.0, 40.7, 39.4, 
33.2, 33.0, 32.8, 28.3, 28.1, 24.2, 22.3, 21.3, 18.8, 18.7, 16.7; HRMS-ES (m/z): calcd 
for C20H32O2 [M]+: 304.24022, found 304.2412. 
4.1.23. Preparation of (1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-5-(prop-2-ynyl)-
4,4a',5,5',6',7', 8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene] (26). 
Aldehyde 24 (148 mg, 0.48 mmol) was dissolved in dry CH2Cl2 (5 mL, 0.1 M) at 0 ºC 
under argon atmosphere. Triphenylphosphine (514 mg, 1.96 mmol), triethylamine (0.3 
mL, 1.96 mmol) and CBr4 (325 mg, 0.98 mmol) were added. The mixture was stirred for 
15 min. and the work-up was carried out by addition of NaHCO3 saturated solution. The 
product was extracted with Et2O (3 x 25 mL), washed with brine, dried over MgSO4, 
filtered and concentrated in vacuum. The dibromoolefin 25 obtained was used without 
purification in the next reaction. The crude material was dissolved in THF (5 mL, 0.1 M) 
and cooled at -78 ºC under argon with stirring. A solution of n-BuLi (0.36 mL, 2.7 M in 
heptane) was added using triphenylmethane as indicator. After 30 min. a NH4Cl 
saturated solution was added and the product was extracted with Et2O (3 x 25 mL). 
The organic layer was washed with brine, dried over MgSO4, filtered and concentrated 
in vacuum. The residue was purified by column chromatography on silica gel, using a 
mixture of n-hexane-ethyl acetate as eluent, to afford 26 as a clear oil (78 mg, 53% 
total yield). [α]D25 = -77.5 (c 0.48, CHCl3); 1H NMR (500 MHz, CDCl3): δ 5.53 (s, 1H), 
2.57  (dd, J = 8 and 2 Hz, 1H), 2.71 (t, J = 8 and 2 Hz, 1H), 2.19 (m, 3H), 2.00 (s, 1H), 
1.91-1.78 (m, 2H), 1.79 (bs, 3H), 1.75-1.62 (m, 1H), 1.58-1.45 (m, 2H), 1.41 (s, 3H), 
1.32-1.23 (m, 2H), 0.92 (s, 3H), 0.91 (s, 3H), 0.89 (s, 3H), 0.84 (s, 3H); 13C NMR (100 
MHz, CDCl3): δ 134.9, 126.6, 91.2, 82.9, 82.5, 69.3, 42.6, 42.0, 40.9, 38.1, 33.4, 33.2, 
32.9, 32.8, 28.3, 26.8, 24.2, 22.4, 21.3, 18.8, 16.7; HRMS-ES (m/z): calcd for C21H32O 
[M]+: 300.2453, found 300.2453. 
4.1.24. General procedure for Huisgen reaction. Preparation of (4-decyl-1-(2-
((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-
spiro[furan-2,1'-naphthalene]-5-yl)ethyl)-1H-1,2,3-triazole (27). 
The azide 23 (53.7 mg, 0.16 mmol) and 1-dodecyne (35µL, 0.16 mmol) were 
suspended in a 1:1 mixture of water and ethanol (0.1 M). Sodium ascorbate (9.6 mg, 
0.05 mmol) and copper(II) sulfate pentahydrate (4 mg, 0.02 mmol) were added. The 
resulting mixture was stirred at room temperature for 24 h. Then, the reaction was 
diluted with water, extracted with ethyl acetate (10 mL×3), dried over MgSO4, filtered, 
and concentrated in vacuum. The residue was purified by column chromatography on 
silica gel using a mixture of n-hexane-ethyl acetate as eluent, to obtain the pure 
product 27 (38.6 mg, yield 48%) as a clear oil. [α]D25 = -64.35 (c 0.20, CHCl3); 1H NMR 
(500MHz, CDCl3): δ 7.32 (s, 1H), 5.51 (s, 1H), 4.46 (t, J = 8 Hz, 2H), 2.71 (t, J = 8 Hz, 
2H), 2.19 (m, 3H), 2.15-1.78 (m, 5H), 1.74 (bs, 3H), 1.71-1.49 (m, 5H), 1.45-1.08 (m, 
18H) 1.28 (s, 3H), 0.92 (t, J = 7 Hz, 3H), 0.91 (s, 3H), 0.90 (s, 3H), 0.82 (s, 3H); 13C 
NMR (100MHz, CDCl3): δ 148.3, 134.9, 126.6, 120.6, 90.6. 81.3, 68.0, 47.0, 43.7, 42.7, 
42.1, 40.7, 39.7, 33.2, 33.0, 32.8, 31.9, 29.6, 29.5 (2C), 29.3, 28.1, 26.9, 25.7, 24.3, 
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22.7, 22.2, 21.3, 18.8, 18.4, 16.7, 14.1; HRMS-ES (m/z): calcd for C32H55N3O [M]+: 
497.4345, found 497.4329. 
4.1.25. Preparation of 4-(3-ethynylphenyl)-1-(2-((1'R,5S,8a'S)-2',5,5',5',8a'-
pentamethyl-4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-
yl)ethyl)-1H-1,2,3-triazole (28). 
This compound was prepared by General procedure for Huisgen reaction using 50 mg 
of azide 23 (0.15 mmol) and 9.5 mg of 1,3-diethynilbenzene (0.075 mmol) to obtain 54 
mg of 28 (78% yield) as a white solid: mp 129-131 ºC. [α]D20 = -175.6 (c 1.57, CHCl3); 
IR νmax, cm-1 (KBr): 3311 (Csp-H), 3130 (=C-H), 2966, 2916, 2866, 2114 (Csp- Csp), 
1479, 1373, 1232, 1001, 804, 656, 619; 1H NMR (500MHz, CDCl3): δ 7.92 (s, 1H, H-
5’), 7.86 (m, 2H, H-9’ and H-11’), 7.46 (d, J = 6.3 Hz, 1H, H-7’),  7.39 (t, J = 7.6 Hz, 1H, 
H-10’), 5.50 (s, 1H, H-7), 4.57 (t, J = 7.6 Hz, 2H, H-15), 3.12 (s, 1H, H-13’), 2.25 (t, J = 
7.6 Hz, 2H, H-14), 2.01 (m, 1H, H-6A) 1.99 (m, 1H, H-11A), 1.98 (m, 1H, H-12A), 1.83 
(m, 2H, H-11B and H-12B), 1.78 (m, 1H, H-6B), 1.74 (s, 3H, H-17), 1.69 (m, 1H, H-5), 
1.63 (m, 1H, H-1A), 1.56 (m, 2H, H-2), 1.44 (m, 1H, H-1B), 1.39 (m, 1H, H-3A), 1.30 (s, 
3H, H-16), 1.22 (m, 1H, H-3B), 0.91 (s, 3H, H-19), 0.87 (s, 3H, H-18), 0.82 (s, 3H, H-
20); 13C NMR (100MHz, CDCl3): δ 146.6 (C-4’), 134.8 (C-8), 131.5 (C-5’), 131.2 (C-6’), 
129.2 (C-9’), 128.8 (C-7’), 126.7 (C-7), 126.0 (C-10’), 122.6 (C-8’), 120.2 (C-11’), 90.8 
(C-9), 83.3 (C-12’), 81.4 (2-C, C-13’ and C-13), 47.2 (C-15), 43.5 (C-14), 42.8 (C-5), 
42.1 (C-3), 40.7 (C-10), 40.1 (C-12), 33.2 (C-4), 33.0 (C-18), 32.8 (C-1), 28.1 (C-6), 
27.0 (C-16), 24.2 (C-11), 22.3 (C-19), 21.2 (C-17), 18.8 (C-2), 16.7 (C-20); HRMS-ES 
(m/z): calcd for C30H39N3O [M]+: 457.3093, found 457.3088. 
 
4.1.26. Preparation of 1-(2-((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl)-4-
(((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-
spiro[furan-2,1'-naphthalene]-5-yl)methyl)-1H-1,2,3-triazole (29). 
This compound was prepared by General procedure for Huisgen reaction using 48.0 
mg of azide 23 (0.14 mmol) and 44.3 mg of alquine 26 (0.14 mmol) to obtain 58.5 mg 
of 29 (64% yield) as a clear oil. [α]D25 = -103.33 (c 0.12, CHCl3); 1H NMR (500MHz, 
CDCl3): δ 7.39 (s, 1H), 5.51 (s, 2H), 4.44 (t, J= 8 Hz, 2H), 3.00 (s, 2H), 2.18 (m, 4H), 
2.06 (m, 6H), 1.98-1.73 (m, 6H), 1.74 (bs, 3H), 1.69 (s, 3H), 1.68-1.47 (m, 6H), 1.41 
(m, 5H), 1.25 (s, 3H), 1.20 (m, 4H), 1.18 (s, 3H), 0.91 (s, 3H), 0.90 (s, 3H), 0.89 (s, 3H), 
0.88 (s, 3H), 0.81 (s, 3H); 13C NMR (100MHz, CDCl3): δ 144.9, 135.5, 134.8, 126.6, 
126.2, 122.7, 90.6, 90.5, 82.7, 81.3, 60.4, 47.0, 43.6, 42.7, 42.6, 42.1 (2C), 40.8, 40.7, 
39.6, 39.5, 38.4, 33.3, 33.2, 33.1, 33.0, 32.8, 29.7, 28.3, 28.1, 27.2, 26.9, 24.3 (2C), 
22.3 (2C), 21.3, 21.0, 18.8, 16.7, 14.2; HRMS-ES (m/z): calcd for C41H65N3O2 [M]+: 
631.5077, found 631.5073. 
4.1.27. Preparation of 1,4-bis(1-(2-((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl)-1H-
1,2,3-triazol-4-yl)butane (30). 
This compound was prepared by General procedure for Huisgen reaction using 27.0 
mg of azide 23 (0.08 mmol) and 5 µL of 1,7-octadiyne (0.04 mmol) to obtain 22.4 mg of 
30 (64% yield) as a clear oil, yield 64%. [α]D25 = -84.57 (c 0.31, CHCl3); 1H NMR 
(500MHz, CDCl3): δ 7.34 (s, 2H, H-5’), 5.50 (s, 2H, H-7), 4.46 (t, J = 7.6 Hz, 4H, H-15), 
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2.74 (t, J = 7.14 Hz, 4H, H-6’), 2.18 (m, 4H, H-14), 2.03 (m, 2H, H-11A), 1.95 (m, 2H, 
H-12A), 1.85 (m, 2H, H-11B), 1.80 (m, 8H, H-6 and H-7’), 1.79 (m, 2H, H-12B), 1.73 (s, 
6H, H-17), 1.70 (m, 2H, H-5), 1.63 (m, 2H, H-1A), 1.61 (m, 4H, H-2), 1.43 (m, 2H, H-
1B), 1.41 (m, 2H, H-3A), 1.26 (s, 6H, H-16), 1.21 (m, 2H, H-3B), 0.91 (s, 6H, H-19), 
0.89 (s, 6H, H-18), 0.81 (s, 6H, H-20); 13C NMR (100MHz, CDCl3): δ 147.7 (2C, C-4’), 
134.8 (2C, C-8), 126.3 (2C, C-7), 120.6 (2C, C-5’), 90.8 (2C, C-9),  81.3 (2C, C-13),  
47.1(2C, C-15), 43.7 (2C, C-14), 42.7 (2C, C-5), 42.1 (2C, C-3), 40.7 (2C, C-10), 39.8 
(2C, C-12), 33.2 (2C, C-4), 33.0 (2C, C-18), 32.8 (2C, C-1), 28.5 (2C, C-6), 28.2 (2C, 
C-7’), 26.9 (2C, C-16), 25.2 (2C, C-6’), 24.3 (2C, C-11), 22.3 (2C, C-19), 21.3 (2C, C-
17), 18.8 (2C, C-2), 16.7 (2C, C-20). 
4.1.28. Preparation of 1,3-bis(1-(2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl)-1H-
1,2,3-triazol-4-yl)benzene (31). 
This compound was prepared by General procedure for Huisgen reaction using 87.0 
mg of azide 23 (0.26 mmol) and 17 µL of 1,3-diethynylbenzene (0.13 mmol) to obtain 
51.0 mg of 31 (51% yield) as a white solid: mp 101-103 ºC. [α]D20 = -144.5 (c 8.8, 
CHCl3); IR νmax, cm-1 (KBr): 3136 (=C-H), 2962, 2926, 2870, 1699, 1460, 1379, 1261, 
1101, 1020, 800; 1H NMR (500MHz, CDCl3): δ 8.28 (s, 1H), 7.91 (s, 2H), 7.82 (dd, J = 
8 and 2Hz, 2H), 7.49 (t, J = 8 Hz, 1H), 5.52 (s, 2H), 4.58 (m, 4H), 2.28 (m, 4H), 2.17-
1.92 (m, 8H), 1.89-1.78 (m, 6H), 1.77 (s, 6H), 1.74-1.49 (m, 6H), 1.46-1.38 (m, 4H), 
1.32 (s, 6H), 1.29-1.10 (m, 2H), 0.92 (s, 6H), 0.88 (s, 6H), 0.83 (s, 6H); 13C NMR 
(100MHz, CDCl3): δ 134.7 (2C), 131.4 (2C), 126.7 (2C), 125.2 (2C), 122.8 (2C), 120.0 
(2C), 90.7 (2C), 81.3 (2C), 77.2 (2C), 47.3 (2C), 43.7 (2C), 42.7 (2C), 42.1 (2C), 40.7 
(2C), 39.9 (2C), 33.2 (2C), 33.0 (2C), 32.8 (2C), 28.1 (2C), 26.9 (2C), 24.2 (2C), 22.3 
(2C), 21.3 (2C), 18.8 (2C), 16.7 (2C); HRMS-ES (m/z): calcd for C50H72N6O2 [M+H]+: 
788.5717, found 788.5724. HRMS-ESI (m/z): calcd for C50H72N6O2Na [M+Na]+: 
811.5614, found 811.5606. 
4.1.29. Preparation of 1,3-bis((1-(2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl)-1H-
1,2,3-triazol-4-yl)methoxy)benzene (32). 
This compound was prepared by General procedure for Huisgen reaction using 100.0 
mg of azide 23 (0.30 mmol) and 28.0 mg of 1,3-bis(prop-2-yn-1-yloxy)benzene (0.15 
mmol) to obtain 59.0 mg of 32 (46% yield) as a white solid: mp 75-77 ºC. [α]D20 = -
123.4 (c 1.08, CHCl3); 1H NMR (500MHz, CDCl3): δ 7.67 (bs, 2H), 7.20 (t, J = 8 Hz, 
1H), 6.63 (s, 1H), (6.62 (d, J = 8 Hz, 2H), 5.49 (bs, 2H), 5.19 (s, 4H), 4.51 (m, 4H), 2.21 
(t, J = 8, 4H), 2.15-1.90 (m, 8H), 1.90-1.75 (m, 6H), 1.72 (s, 6H), 1.71-1.46 (m, 8H), 
1.45-1.30 (m, 2H) 1.28 (s, 6H), 1.28-1.15 (m, 2H), 0.91 (s, 6H), 0.89 (s, 6H), 0.81 (s, 
6H); 13C NMR (100MHz, CDCl3): δ 159.5 (2C), 144.0 (2C), 134.7, 130.0, 126.6 (2C), 
122.9 (2C), 107.5 (2C), 102.2 (2C), 90.7 (2C), 81.2 (2C), 62.1 (2C), 47.4 (2C), 43.6 
(2C), 42.7 (2C), 42.1 (2C), 40.7 (2C), 39.9 (2C), 33.2 (2C), 33.0 (2C), 32.7 (2C), 28.0 
(2C), 26.9 (2C), 24.3 (2C), 22.3 (2C), 21.3 (2C), 18.8 (2C), 16.7 (2C); HRMS-ESI (m/z): 
calcd for C52H76N6O4Na [M+Na]+: 871.5825, found 871.5832. 
4.1.30. Preparation of 2-((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl-1H-
imidazole-1-carboxylate (33). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
To a solution of alcohol 4 (1 g, 3.26 mmol) in CH2Cl2 (65 mL, 0.05 M) was added 
carbonyl diimidazole (2.64 g, 16.4 mmol). The reaction mixture was heated to 40 ºC 
and stirred for 4.5 h. Solvent was removed and the residue subjected to a flash 
chromatography to provide carbonyl imidazole 33 (927 mg, yield 71%) as clear oil. 
[α]D20 = -117.90 (c 15.54, CHCl3); IR νmax, cm-1 (KBr): 3124, 2970, 1747 (C=O), 1672 
(C=C), 1466, 1379,1271, 1005, 872, 758; 1H NMR (500MHz, CDCl3): δ 8.11 (s, 1H, H-
2’), 7.41 (s, 1H, H-4’), 7.05 (s, 1H, H-5’), 5.46 (bs, 1H, H-7), 4.56 (m, 2H, H-15), 2.16 
(dt , J = 14 and 7 Hz, 1H, H-14A), 2.07 (m, 1H, H-11A), 2.03 (m, 1H, H-14B), 2.00 (m, 
1H, H-12A), 1.96 (m, 1H, H-6A), 1.79 (m, 2H, H-11B and H-12B), 1.76 (s, 3H, H-17), 
1.76 (m, 1H, H-6B), 1.67 (m, 1H, H-5), 1.61 (m, 2H, H-3), 1.51 (m, 2H, H-2), 1.40 (m, 
2H, H-1), 1.28 (s, 3H, H-16), 0.89 (s, 3H, H-19), 0.85 (s, 3H, H-18), 0.80 (s, 3H, H-20); 
13C NMR (100MHz, CDCl3): δ 137.1 (C-2’), 134.8 (C-8), 130.5 (C-4’), 126.6 (C-7), 
117.1 (C-5’), 90.6 (C-9), 81.3 (C-13), 65.9 (C-15), 42.6 (C-5), 42.0 (C-3), 41.8 (C-14), 
40.7 (C-10), 40.0 (C-12), 33.2 (C-4), 33.0 (C-18), 32.7 (C-1), 27.1 (C-16), 24.2 (2C, C-
11 and C-6), 22.3 (C-19), 21.3 (C-17), 18.7 (C-2), 16.7 (C-20); HRMS-ES (m/z): calcd 
for C24H37N2O3 [M+H]+: 401.2799, found 401.2791. 
4.1.31. General procedure for synthesis of carbamates derivatives. Preparation of 2-
((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-
spiro[furan-2,1'-naphthalene]-5-yl)ethyl-3-(dimethylamino)propylcarbamate (34). 
A solution of the carbonyl imidazole 33 (24.2 mg, 0.06 mmol) was dissolved in 
acetonitrile (0.12 mL, 0.5 M). Methyl iodide (0.75 mL, 12 mmol) was added and the 
solution was heated to 60 °C for 2 h. The volatiles  were removed by evaporation and 
the residue was redissolved in methylene chloride (1.5 mL, 0.04M), 3-(dimethylamino)-
1-propylamine (0.15 mL, 1.2 mmol) was added, and the resulting reaction mixture was 
stirred 4h. The volatiles were removed by evaporation and the crude residue was 
purified by flash chromatography to give 20.7 mg of 34 (79% yield) as a clear oil. [α]D25 
= -38 (c 0.1, CHCl3); 1H NMR (500MHz, CDCl3): δ 5.53 (bs, 1H), 5.49 (bs, 1H), 4.16 
(bs, 2H), 3.26 (m, 2H), 2.58 (m, 2H), 2.40 (bs, 6H), 2.06 (m, 6H), 1.78 (m, 1H), 1.76 (s, 
3H), 1.69 (m, 4H), 1.51 (m, 2H), 1.40 (m, 2H), 1.23 (s, 3H), 0.90 (s, 3H), 0.88 (s, 3H), 
0.81 (s, 3H); 13C NMR (100MHz, CDCl3): δ 156.9, 135.2, 126.2, 90.2, 81.9, 62.6, 56.8, 
44.4, 42.6, 42.4, 42.0, 40.7, 39.2 (2C), 33.2, 32.9, 32.8, 29.7, 28.4, 27.0, 26.3, 24.2, 
22.4, 21.2, 18.8, 16.7; HRMS-ESI (m/z): calcd for C26H46N2O3Na [M+Na]+: 457.3406, 
found 457.3407. 
4.1.32. Preparation of 2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-4,4a',5,5',6',7',8',8a'-
octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl prop-2-ynylcarbamate (35). 
This compound was prepared by General procedure for synthesis of carbamates 
derivatives using 97.0 mg carbonyl imidazole 33 (0.24 mmol) and 0.35 mL of 
propargylamine (5.52 mmol) to obtain 78 mg of 35 (83% yield) as a white solid: mp 
116-118 ºC. [α]D20 = -113.7 (c 0.918, CHCl3); 1H NMR (500MHz, CDCl3): δ 5.49 (bs, 
1H), 4.83 (bs, 1H), 4.20 (m, 2H), 3.98 (bs, 2H), 2.25 (m, 1H), 2.10-1.88 (m, 4H), 1.78-
1.60 (m, 4H), 1.76 (s, 3H), 1.59-1.45 (m, 3H), 1.40-1.35 (m, 2H), 1.28-1.20 (m, 2H), 
1.23 (s, 3H), 0.91 (s, 3H), 0.88 (s, 3H), 0.82 (s, 3H); 13C NMR (100MHz, CDCl3): δ 
135.2, 134.2, 126.3, 90.4, 81.8, 80.8, 71.5, 63.2, 42.6, 42.3, 42.0, 40.7, 39.3, 33.2, 
32.9, 32.8, 29.7, 28.4, 27.0, 24.2, 22.4, 21.2, 18.8, 16.7; HRMS-ES (m/z): calcd for 
C24H37NO3 [M]+: 387.2773, found 387.2761. 
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4.1.33. Preparation of bis(2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl) ethane-
1,2-diyldicarbamate (36). 
This compound was prepared by General procedure for synthesis of carbamates 
derivatives using 100.0 mg carbonyl imidazole 33 (0.25 mmol) and 0.38 mL of 
ethylenediamine (5.75 mmol) to obtain 46 mg of 36 (51% yield) as a white solid: mp 
170-172 ºC. [α]D20 = -126.7 (c 1.12, CHCl3); 1H NMR (500MHz, CDCl3): δ 5.50 (bs, 2H), 
4.99 (bs, 2H), 4.17 (m, 4H), 3.30 (bs, 4H), 2.09-1.80 (m, 8H), 1.79-1.62 (m, 2H), 1.77 
(s, 6H), 1.60-1.52 (m, 4H), 1.51-1.38 (m, 10H), 1.35-1.22 (m, 4H), 1.20-1.09 (m, 2H), 
1.23 (s, 6H), 0.91 (s, 6H), 0.88 (s, 6H), 0.82 (s, 6H); 13C NMR (100MHz, CDCl3): δ 
178.8 (2C), 135.2 (2C), 126.2 (2C), 115.0 (2C), 90.6 (2C), 81.8 (2C), 62.9 (2C), 56.5 
(2C), 42.6 (2C), 42.3 (2C), 42.0 (2C), 40.7 (2C), 33.2 (2C), 33.0 (2C), 32.8 (2C), 28.4 
(2C), 27.0 (2C), 24.2 (2C), 22.4 (2C), 21.3 (2C), 18.8 (2C), 16.7 (2C); HRMS-ESI (m/z): 
calcd for C44H72N2O6Na [M+Na]+: 747.5294, found 747.5262. 
4.1.34. Preparation of 2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-4,4a',5,5',6',7',8',8a'-
octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl(1-(2-((1'R,5S,8a'S)-
2',5,5',5',8a'-pentamethyl-4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-
naphthalene]-5-yl)ethyl)-1H-1,2,3-triazol-4-yl)methylcarbamate (37). 
This compound was prepared by General procedure for Huisgen reaction using 81.0 
mg of azide 23 (0.24 mmol) and 43.0 mg of propynylcarbamate 35 (0.11 mmol) to 
obtain 51 mg of 37 (64% yield) as a white solid, mp 69-71 ºC. [α]D20 = -137.1 (c 1.022, 
CHCl3); 1H NMR (500MHz, CDCl3): δ 7.58 (s. 1H), 5.49 (bs, 2H), 5.27 (bs, 1H), 4.46 
(m, 4H), 4.16 (m, 2H), 2.19 (m, 2H), 2.12-1.86 (m, 7H), 1.85-1.70 (m, 8H), 1.75 (s, 3H), 
1.73 (s, 3H), 1.71-1.45 (m, 6H), 1.42-1.32 (m, 4H), 1.28-1.20 (m, 3H), 1.27 (s, 3H), 
1.21 (s, 3H), 0.91 (s, 3H), 0.90 (s, 6H), 0.89 (s, 3H), 0.81 (s, 6H); 13C NMR (100MHz, 
CDCl3): δ 176.2, 156.6, 135.2, 134.7, 126.7 (2C), 126.2 (2C), 122.1, 90.7, 90.2, 81.8, 
81.2, 62.9, 47.3, 43.6, 42.6 (2C), 42.3, 42.1 (2C), 40.7 (2C), 39.9, 39.2, 36.3, 33.2, 
33.0, 32.9, 32.8, 32.7, 28.4, 28.0, 27.0, 26.9, 24.3, 24.2, 22.4, 21.3 (2C), 18.8 (2C), 
16.7 (2C); HRMS-ESI (m/z): calcd for C44H70N4O4Na [M+Na]+: 741.5294, found 
741.5292. 
 
4.2. Cells, culture and plating 
The human solid tumor cell lines HBL-100 (breast), HeLa (cervix), SW1573 (non-small 
cell lung), T-47D (breast) and WiDr (colon) were used in this study. Cells were 
maintained in 25 cm2 culture flasks in RPMI 1640 supplemented with 5% heat 
inactivated fetal calf serum and 2 mM L-glutamine in a 37 ºC, 5% CO2, 95% humidified 
air incubator. Exponentially growing cells were trypsinized and resuspended in 
antibiotic containing medium (100 units penicillin G and 0.1 mg of streptomycin per 
mL). Single cell suspensions displaying >97% viability by trypan blue dye exclusion 
were subsequently counted. After counting, dilutions were made to give the appropriate 
cell densities for inoculation onto 96-well microtiter plates. Cells were inoculated in a 
volume of 100 µL per well at densities of 20,000 (WiDr), 15,000 (T-47D ) and 10,000 
(HeLa, SW1573 and HBL-100) cells per well, based on their doubling times. 
4.3. Antiproliferative tests 
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Chemosensitivity tests were performed using the SRB assay of the NCI with slight 
modifications. Briefly, pure compounds were initially dissolved in DMSO at 400 times 
the desired final maximum test concentration. Control cells were exposed to an 
equivalent concentration of DMSO (0.25% v/v, negative control). Each agent was 
tested in triplicates at different dilutions in the range 1–100 µM. The drug treatment was 
started on day 1 after plating. Drug incubation times were 48 h, after which time cells 
were precipitated with 25 µL ice-cold 50% (w/v) trichloroacetic acid and fixed for 60 min 
at 4 ºC. Then the SRB assay was performed. The optical density (OD) of each well was 
measured at 492 nm, using BioTek’s PowerWave XS Absorbance Microplate Reader. 
Values were corrected for background OD from wells only containing medium. The 
percentage growth (PG) was calculated with respect to untreated control cells (C) at 
each of the drug concentration levels based on the difference in OD at the start (T0) 
and end of drug exposure (T), according to NCI formulas. Therefore, if T is greater than 
or equal to T0 the calculation is 100 × [(T–T0)/(C–T0)]. If T is less than T0 denoting cell 
killing the calculation is 100 × [(T–T0)/(T0)]. The effect is defined as percentage of 
growth, where 50% growth inhibition (GI50) represents the concentration at which PG is 
+50. With these calculations a PG value of 0 corresponds to the amount of cells 
present at the start of drug exposure, while negative PG values denote net cell kill. 
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Figure 1: Grindelic acid and 1-(α)-hydroxygrindelic acid 
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Scheme 1: Reagents and conditions: a) CH2N2, Et2O, rt. 94%; b) LiAlH4, THF, 70 ºC, 
91%; c) SO3.Py, Et3N, DMSO, Ph3P=C(CH3)CO2Et, CH2Cl2, rt, 74%; d) DIBAL-H, Et2O, 
0 °C, 82-89%; e) SO 3.Py, Et3N, DMSO, Ph3P=CHCO2Et, CH2Cl2, rt, 94%; f) Ti(OPr-i)4, 
R,R-(+)-DET, TBHP, CH2Cl2, -20 ºC, 71%; g) Ti(OPr-i)4, S,S-(-)-DET, TBHP, CH2Cl2, -
20 ºC, 85%. 
 
 
Scheme 2: Reagents and conditions: a) MsCl, TEA, CH2Cl2, 0 °C, 12h, 90%; b) NaN 3, 
DMF, 40 °C, 48h, 80%; c) (COCl) 2, Et3N, DMSO, Cl2CH2, -78 °C, 30 min, 99%; d) 
PPh3, CBr4, Et3N, Cl2CH2, 0 °C, 15 min; e) n-BuLi, THF, -78 °C, 30 min, 53% . 
 
 
Scheme 3: Reagents and conditions: a) CDI, Cl2CH2, 40 °C, 16 h, 71%; b) i: ICH 3, 
acetonitrile, 60 ºC, 2h, ii: RNH2, Cl2CH2, 4h, rt, 79-83%; c) i: ICH3, acetonitrile, 60 ºC, 
2h, ii: ethylenediamine, Cl2CH2, 4h, rt, 51%; d) 23, sodium ascorbate, CuSO4.5H2O, 
H2O-EtOH, rt, 64%. 
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Table 1: Diamides obtained from the 
multicomponent Ugi reaction of grindelic acid (1).a 
 
 
Compound R1 R2 Yield b 
11 
 
 
59 
12 
 
 
75 
13 
 
 
71 
14 
 
 
63 
15 
 
 
79 
16 
 
 
79 
17 
 
 
97 
18 
 
 
78 
19 
 
 
26 
20 
  
23 
21 
 
 
43 
22 
 
 
92 
a All the reactions were carried out using 1 eq of compound 1, 
1 eq of the corresponding amine, 1.2 eq of propanone and 
1.1 eq of the corresponding isocyanide. 
b Isolated yield. 
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Table 2: 1,2,3-triazole obtained by Huisgen 
reaction using mono-alkynes.a 
 
Compound R yield 
27 
 
48 
28 
 
78 
29 
 
64 
a
 All the reactions were carried out using the azide 
23 (1 equiv), alkyne (1 equiv), sodium ascorbate (0.3 
equiv) and copper(II) sulfate pentahydrate (0.12 
equiv) in a 1:1 mixture of water and ethanol (0.1 M).  
b Isolated yield. 
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Table 3: 1,2,3-triazole obtained by Huisgen reaction 
using di-alkynes. a 
 
Compound R yield 
30 
 
64 
31 
 
51 
32 
 
46 
a
 All the reactions were carried out using the azide 23 (1 
equiv), di-alkyne (0.5 equiv), sodium ascorbate (0.3 
equiv) and copper(II) sulfate pentahydrate (0.12 equiv) 
in a 1:1 mixture of water and ethanol (0.1 M).  
b
 Isolated yield. 
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Table 4: In vitro antiproliferative activity against human solid tumor cell lines.a 
 Cell line 
Comp. HBL-100 (breast) 
HeLa 
(cervix) 
SW1573 
(NSCLC) 
T-47D 
(breast) 
WiDr 
(colon) 
1 46 (±10) 60 (±31) 49 (±28) 69 (±5.5) 57 (±13) 
2 >100 >100 >72 (±39) >100 >100 
3 17 (±2.4) 16 (±2.9) 18 (±1.9) 19 (±5.4) 23 (±3.9) 
4 17 (±2.6) 17 (±2.5) 19 (±1.1) 16 (±1.8) 21 (±0.65) 
5 17 (±4.4) 18 (±5.8) 20 (±4.5) 32 (±9.1) 37 (±0.87) 
6 16 (±2.6) 16 (±2.3) 18 (±1.3) 15 (±1.7) 19 (±0.23) 
7 16 (±3.8) 19 (±7.4) 18 (±3.3) 32 (±7.8) 35 (±0.69) 
8 17 (±1.7) 18 (±2.5) 17 (±1.3) 17 (±2.0) 17 (±1.2) 
9 16 (±2.3) 17 (±1.7) 18 (±0.64) 16 (±2.0) 19 (±0.18) 
10 16 (±1.9) 17 (±1.4) 18 (±1.0) 15 (±2.5) 17 (±0.14) 
11 4.6 (±3.9) 5.3 (±5.6) 11 (±1.4) 3.9 (±0.87) 12 (±0.84) 
12 10 (±3.5) 30 (±6.9) 14 (±2.6) 40 (±4.5) 49 (±7.9) 
13 3.7 (±0.31) 4.7 (±0.84) 3.6 (±0.71) 4.4 (±1.0) 5.1 (±0.82) 
14 8.9 (±2.2) 11 (±1.6) 5.1 (±1.9) 31 (±5.8) 38 (±7.8) 
15 1.9 (±0.44) 2.9 (±0.89) 1.8 (±0.51) 3.0 (±0.78) 3.1 (±1.3) 
16 16 (±0.88) 18(±2.0) 16 (±3.3) 19 (±2.3) 12 (±2.4) 
17 0.95 (±0.38) 1.6 (±0.46) 1.2 (±0.54) 1.9 (±0.62) 1.8 (±0.81) 
18 5.4 (±2.1) 5.7 (±2.6) 5.8 (±2.6) 5.3 (±2.5) 6.8 (±0.28) 
19 8.7 (±0.63) 22 (±2.3) 5.9 (±1.2) 21 (±3.5) 37 (±8.2) 
23 >100 >100 >100 >100 >100 
24 14 (±3.5) 17 (±2.6) 17 (±3.3) 26 (±8.1) 15 
26 17 (±1.9) 16 (±1.2) 15 (±2.4) 28 (±10) 4.8 
27 16 (±5.0) 25 (±6.8) 15 (±2.3) 44 (±13) 15 
28 >100 >100 >100 >100 >100 
29 9.3 (±1.4) 17 (±0.82) 11 (±0.5) 17 (±1.0) n.a. 
30 2.9 (±0.49) 2.7 (±0.74) 3.0 (±0.39) 4.3 (±0.63) 1.3 
32 >100 >100 >100 >100 >100 
33 16 (±0.34) 18 (±1.1) 17 (±0.85) 17 (±0.88) 13 
34 6.1 (±0.57) 7.8 (±2.9) 8.0 (±6.9) 4.3 (±0.98) 1.4 
35 14 (±0.35) 14 (±1.6) 13 (±2.3) 16 (±2.4) 12 (±1.9) 
37 >100 >100 >100 >100 >100 
Cisplatin 1.9 (±0.2) 2.0 (±0.3) 3.0 (±0.4) 15 (±2.3) 26 (±5.3) 
Camptothecin 0.23 (±0.05) 0.6 (±0.4) 0.25 (±0.12) 2.0 (±0.5) 1.8 (±0.7) 
a
 Values expressed as GI50 (50% growth inhibition) are given in µM and are means 
of two to four experiments, standard deviation is given in parentheses. 
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Highlights 
• Syntheses of grindelic acid derivatives.  
• Oxy-nitrogenated and nitrogenated groups are key for the cytotoxic activity.  
• The more active derivative showed a GI50 values in the range 0.95-1.8 µM.  
• Labdanes-type diterpenes represent a potential source for new anticancer drug 
candidates. 
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Figure S1. Spectra of Grindelic acid methyl ester (3)  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S2. Spectra of Grindelic alcohol, (4)  
1H-NMR (CDCl3) 
  
13C-NMR (CDCl3) 
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Figure S3. Spectra of (E)-ethyl 2-methyl-4-((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-
pentamethyl-4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-
yl)but-2-enoate, (5).  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S4. Spectra of (E)-2-methyl-4-((1'R,4a'S,5S,8a'S)-2',5,5', 5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)but-2-en-1-ol, 
(6).   
1H-NMR (CDCl3) 
  
13C-NMR (CDCl3) 
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Figure S5. Spectra of (E)-ethyl 4-((1'R,4a'S,5S,8a'S)-2',5,5',5', 8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)but-2-enoate, 
(7).  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S6. Spectra of (E)-2-methyl-4-((1'R,4a'S,5S,8a'S)-2',5, 5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H, 4'H-spiro[furan-2,1'-naphthalene]-5-yl)but-2-en-1-ol, 
(8).  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S7. Spectra of ((2S,3S)-3-(((1'R,4a'S,5S,8a'S)-2',5,5',5', 8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)methyl)oxiran-
2-yl)methanol, (9)  
1H-NMR (CDCl3) 
  
13C-NMR (CDCl3) 
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Figure S8. Spectra of ((2R,3R)-3-(((1'R,4a'S,5S,8a'S)-2',5,5',5', 8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro [furan-2,1'-naphthalene]-5-yl)methyl)oxiran 
-2-yl)methanol, (10)  
1H-NMR (CDCl3) 
  
13C-NMR (CDCl3) 
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Figure S9. Spectra of 2-(N-benzyl-2-((1'R,4a'S,5S,8a'S)-2',5,5', 5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H, 4'H-spiro[furan-2,1'-naphthalene]-5-yl)acetamido)-
N-tert-butyl-2-methylpropanamide, (11)  
1H-NMR (CDCl3) 
  
13C-NMR (CDCl3) 
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Figure S10. Spectra of 2-(N-benzyl-2-((1'R,5S,8α'S)-2',5,5',5',8α'-pentamethyl-
4,4α',5,5',6',7',8',8α-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)acetamido)-2-
methyl-N-(2,3,3-trimethylbutan-2-yl)propanamide, (12)  
1H-NMR (CDCl3) 
  
13C-NMR (CDCl3) 
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Figure S11. Spectra of 2-(N-benzyl-2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)acetamido)-N-
cyclohexyl-2-methylpropanamide, (13)  
1H-NMR (CDCl3) 
  
13C-NMR (CDCl3) 
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Figure S12. Spectra of 2-(N-benzyl-2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)acetamido)-N-
(2,6-dimethylphenyl)-2-methylpropanamide, (14)  
1H-NMR (CDCl3) 
  
13C-NMR (CDCl3) 
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Figure S13. Spectra of 2-(N-benzyl-2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)acetamido)-N-
butyl-2-methylpropanamide, (15)  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S14. Spectra of 2-(N-benzyl-2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)acetamido)-2-
methyl-N-(2-morpholinoethyl)propanamide, (16)  
1H-NMR (CDCl3) 
  
13C-NMR (CDCl3) 
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Figure S15. Spectra of N-benzyl-2-methyl-2-(2-((1'R,5S,8a'S)-2',5,5',5',8a'-
pentamethyl-4,4a',5,5',6',7', 8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)-
N-phenylacetamido)propanamide, (17)  
1H-NMR (CDCl3) 
  
13C-NMR (CDCl3) 
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Figure S16. Spectra of Preparation of N-tert-butyl-2-methyl-2-(2-((1'R,4a'S,5S, 8a'S)-
2',5,5',5',8a'-pentamethyl-4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-
naphthalene]-5-yl)-N-phenylacetamido)propanamide. (18)  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S17. Spectra of N-(2,6-dimethylphenyl)-2-methyl-2-(2-((1'R,5S,8a'S)-
2',5,5',5',8a'-pentamethyl-4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-
naphthalene]-5-yl)-N-phenylacetamido)propanamide, (19)  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S18. Spectra of N-butyl-2-methyl-2-(2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8', 8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)-N-
phenylacetamido)propaneamide, (20)  
1H-NMR (CDCl3) 
  
13C-NMR (CDCl3) 
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Figure S19. Spectra of N-benzyl-2-methyl-2-(2-((1'R,5S,8a'S)-2',5,5',5',8a'-
pentamethyl-4,4a',5,5',6',7', 8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)-
N-phenylacetamido)propanamide, (21)  
1H-NMR (CDCl3) 
  
13C-NMR (CDCl3) 
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Figure S20. Spectra of N-cyclohexyl-2-methyl-2-(2-((1'R,5S,8a'S)-2',5,5',5',8a'-
pentamethyl-4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)-
N-phenylacetamido)propanamide, (22)  
1H-NMR (CDCl3) 
  
13C-NMR (CDCl3) 
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Figure S21. Spectra of Preparation of (1'R,4a'S,5S,8a'S)-5-(2-azidoethyl)-2',5,5',5',8a'-
pentamethyl-4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene], (23)   
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S22. Spectra of 3-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-4,4a',5,5',6',7',8',8a'-
octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)propanal, (24)  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S23. Spectra of (1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-5-(prop-2-ynyl)-
4,4a',5,5',6',7', 8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene], (26)  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S24. Spectra of (4-decyl-1-t-(2-((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl)-1H-
1,2,3-triazole, (27)  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S25. Spectra of 4-(3-ethynylphenyl)-1-(2-((1'R,5S,8a'S)-2',5,5',5',8a'-
pentamethyl-4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-
yl)ethyl)-1H-1,2,3-triazole, (28)  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S26. Spectra of 1-(2-((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl)-4-
(((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-
spiro[furan-2,1'-naphthalene]-5-yl)methyl)-1H-1,2,3-triazole, (29)  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S27. Spectra of 1,4-bis(1-(2-((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl)-1H-
1,2,3-triazol-4-yl)butane, (30)  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S28. Spectra of 1,3-bis(1-(2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl)-1H-
1,2,3-triazol-4-yl)benzene, (31)  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S29. Spectra of 1,3-bis((1-(2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl)-1H-
1,2,3-triazol-4-yl)methoxy)benzene, (32)  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S30. Spectra of 2-((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl-1H-
imidazole-1-carboxylate, (33)  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S31. Spectra of 2-((1'R,4a'S,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl-3-
(dimethylamino)propylcarbamate, (34)  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
  
O
O
H
N
O
H
N
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
33 
 
Figure S32. Spectra of 2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-4,4a',5,5',6',7',8',8a'-
octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl prop-2-ynylcarbamate, (35)  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S33. Spectra of bis(2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-
4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl) ethane-
1,2-diyldicarbamate, (36)  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S34. Spectra of 2-((1'R,5S,8a'S)-2',5,5',5',8a'-pentamethyl-4,4a',5,5',6',7',8',8a'-
octahydro-3H,4'H-spiro[furan-2,1'-naphthalene]-5-yl)ethyl (1-(2-((1'R,5S,8a'S)-
2',5,5',5',8a'-pentamethyl-4,4a',5,5',6',7',8',8a'-octahydro-3H,4'H-spiro[furan-2,1'-
naphthalene]-5-yl)ethyl)-1H-1,2,3-triazol-4-yl)methylcarbamate, (37)  
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Natural products. Starting material: 
Figure S35. Spectra of grindelic acid (1) 
1H-NMR (CDCl3) 
 
13C-NMR (CDCl3) 
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Figure S36. Spectra of 1α-hidroxygrindelic acid (2) 
1H-NMR (CDCl3) 
 
13C-NMR (CCl3) 
 
Note: Additional spectroscopic and spectrometric data available for request to the 
corresponding author. 
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